From July 5-7, 2025, the 42nd China pharmaceutical Industrial Information Annual Conference and Beijing Changping Forum On Life Science were held in Changping, Beijing. Themed "Ignite Life For Future", this conference invited industry regulatory authorities, pharmaceutical companies, research institutions, medical organizations, and outstanding representatives from the industrial chain. Through cutting-edge insights, ecosystem co-construction, and resource alignment, as well as bidirectional empowerment between academia and industry, the conference aims to accelerate the transformation of scientific and technological innovation into industrial applications, activate new momentum for the development of the pharmaceutical industry, explore new pathways together, and jointly create a new future.
During the conference, ASK was honored as an "Excellent Case of Chinese Pharmaceutical R&D Product Line Industrial Enterprises", having won related honors for the "Best Industrial Enterprises in Chinese Pharmaceutical R&D Product Line" for sixteen consecutive years. Adhering to the corporate philosophy of "Research as the Source, Health as the Foundation", ASK focuses on the development of innovative drugs and high-barrier complex formulations, driving development through dual engines of independent innovation and open innovation. Since 2024, the company has had 10 new drugs approved for marketing, 10 active pharmaceutical ingredients (APIs) approved, and 7 new drugs submitted for marketing authorization. Currently, there are 42 major projects under development, including 9 key innovative drugs that have been publicly disclosed, with several other innovative drugs in the preclinical research stage.
The innovative drug Lierutinib Tablets (Aoyixin?), launched in January 2025, was selected for the "Biomedical Innovation Achievements Exhibition".
Note: The "Excellent Case of Chinese Pharmaceutical R&D Product Line Industrial Enterprises" aims to recognize companies that excel in pharmaceutical R&D, affirming and evaluating their R&D innovation capabilities, product line layout, and clinical progress. The "Biomedical Innovation Achievements Exhibition" reflects the significant achievements made by key enterprises through continuous technological accumulation and forward-looking R&D planning. Aosaikang's recognition this time is not only an acknowledgment of its R&D strength but also a confirmation of its contributions to advancing the pharmaceutical industry.
Biomedical Innovation Achievements Exhibition——Innovative Drug Lierutinib Tablets (Aoyixin?)
The innovative drug Lierutinib Tablets (Aoyixin?), launched in January 2025, is the first Class 1 new drug of the year in Jiangsu Province.
The core features of Aoyixin? are: original innovative molecular design with a unique naphthylamine structure as a third-generation EGFR-TKI. Clinical data shows that compared to similar drugs, it has a higher disease control rate and stronger ability to reduce the risk of intracranial progression. Its Phase III clinical study results were published in the internationally renowned medical journal "The Lancet Respiratory Medicine". This original innovation, which addresses significant unmet clinical needs, directly embodies ASK's commitment to scientific and technological innovation as its core driving force and cultivation of new quality productive forces. This achievement has also received support from the National Major New Drug Innovation Program.
In the future, ASK will continue to uphold its corporate mission of "For Health, Healthy Actions", increase R&D investment, deepen the integration of industry, academia, and research, accelerate the launch of more "hard-core" innovative drugs, benefit the public with higher quality and more accessible products, and contribute to strengthening China's pharmaceutical industry's new quality productive forces and promoting high-quality industry development!